Should DCGI (Drug Controller General of India) take back febuxostat drug from the market?

Should DCGI (Drug Controller General of India) take back febuxostat drug from the market?

Dr. K K Aggarwal, President Heart Care Foundation of India and Group Editor in Chief MEDtalks, will talk on the topic whether DCGI (Drug Controller General of India) should withdraw febuxostat from the market in this video. Febuxostat is given to reduce uric acid in the body. It is often misused drug in our country. If the uric acid levels are more than 10 and patient is asymptomatic then no need to treat them. High uric acid is the indicator of metabolic syndrome. It is been rejected twice by USFDA stating that it causes cardiovascular complications.

uricacid
Dr. KK Aggarwal

Recipient of Padma Shri, Vishwa Hindi Samman, National Science Communication Award and Dr B C Roy National Award, Dr Aggarwal is a physician, cardiologist, spiritual writer and motivational speaker. He was the Past President of the Indian Medical Association and President of Heart Care Foundation of India. He was also the Editor in Chief of the IJCP Group, Medtalks and eMediNexus

 More FAQs by Dr. KK Aggarwal